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(79 pts)No HCT
(38 pts)P-value
logistic
regressionUnfavorable cytogenetics (n) 30 (37%) 7 (18%) 0.18
Secondary AML (n) 39 (49%) 15 (39%) 0.32
Early relapse (n) (>5%
marrow blasts within
4.9 months of CR1
(range 0.9-10, median 3.75)0 (0%) 13 (34%) <0.001Twenty-four of the 38 (63%) non-HCTpatients wereHLA-typed
and matched donors were found for 13 of these 24 patients (54%; 5
related, 8 unrelated). Seven of the 14 non-typed patients (50%) had
financial barriers or refusedHLA-typing. Only 2 of these 38 (5%) re-
ceived HCT beyond CR1.
Conclusion: These data suggest that HCT can be performed in
CR1 in the majority of high-risk AML patients in whom it is cur-
rently recommended. Patients in whom HCT is not done are char-
acterized by a poorer performance status (but not older age) and by
early relapse. In the absence of these 2 factors,.75%of patients with
high-risk AML under the age of 75 can receive HCT in CR1. A na-
tional study is planned to assess the extent to which these results can
be generalized.229
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A promising area of investigation in AML is the development of
cancer vaccines that educate host immunity to target leukemia cells,
including the stem cell compartment. Our group has developed
a cancer vaccine in which dendritic cells (DCs) are fused to autolo-
gous tumor cells, resulting in the presentation of multiple tumor an-
tigens and eliciting a broad immune response. A challenge to
developing a more effective tumor vaccine is overcoming inhibitory
pathways, including the PD1/PDL1 pathway, contributing to tu-
mor-mediated immune suppression. We are conducting a clinical
trial in which AML patients who are in remission following chemo-
therapy receive three monthly doses of DC/AML fusion cells alone
(cohort 1) or in conjunction with anti-PD1 antibody, CT-011 (co-
hort 2). To date, 21 patients (mean age 57 years) have been enrolled.
Patients underwent tumor collection from either bone marrow (N5
14), 20 cc of peripheral blood (N 5 5), or leukapheresis product
(N 5 2). The mean tumor yield and viability was 8.43x108 cells
and 99% respectively. Patients achieving remission following che-
motherapy underwent leukapheresis for DC generation. Adherent
peripheral blood mononuclear cells were cultured in the presence
of GM-CSF and IL-4 for 5-7 days, and exposed to TNFa for 48
hours to generate mature DCs. One patient died during induction
chemotherapy, one patient did not collect a sufficient number of tu-
mor cells for vaccine generation, and 3 patients were removed from
study to undergo allogeneic transplantation. Vaccine was generated
in 12 patients at a dose of 5x106 fusions cells, mean fusion efficiency
of 31%, and viability of 87%. As ameasure of their activity as antigen
presenting cells, the capacity of fusion cells to stimulate allogeneic T
cell proliferation ex vivo was quantified. In contrast to the leukemia
cells (mean stimulation index (SI) 4.4), the DC and fusion cells were
potent stimulators (mean SI 24.1 and 15.5, respectively). Vaccination
was initiatedwithin 12 weeks from count recovery following comple-
tion of chemotherapy. 4 patients have completed vaccinations, and 3
are undergoing vaccination. Vaccine related adverse events includedvaccine site reactions, ankle pain and edema. Biopsy of a vaccine site
reaction demonstrated a dense T cell infiltrate. Peripheral blood is
being collected prior to and serially following vaccination. Immune
response targeting leukemia cells, leukemic stem cells, and leukemia
associated antigens will be assessed.230
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CLLpts who are fludarabine-refractory or possess unfavorable cy-
togenetics have short survivals with conventional therapies. Non-
myeloablative allogeneic HCT may provide long-term disease
control. Disease progression is the major risk within the first year
after HCT (median 3.3 months), until development of graft-versus-
leukemia (GVL) effects. Treatment with anti-CD20monoclonal an-
tibody (rituximab) in the early post-transplant period could improve
disease control: 1) directly by antibody-dependent cytotoxicity and
2) indirectly by promoting cross-presentation of cell-derived pep-
tides causing earlier and/or more robust GVL effects. To date, 20
pts have been enrolled on a phase II trial comprising fludarabine,
30 mg/m2 (days -4, -3, and -2) and 2 Gy total body irradiation (day
-1) together with rituximab, 375 mg/m2 (days -3, +10, +24, and
+38). Grafts were from HLA-matched related (n 5 6) or unrelated
(n 5 14) donors. Median age was 61 (range 37-74) years. Pts were
older, had higher comorbidity scores, more frequently received un-
related grafts, and more frequently had unfavorable cytogenetics
compared to a historical control group of 128 pts treated with the
same regimen except for peri-transplant rituximab (Table).
Table. Comparison of Pre-transplant Characteristics Among
Pts Treated with Nonmyeloablative Conditioning and Alloge-
neicHCTEitherWith (n520) orWithout (n5128)Rituximab
No Rituximab Rituximab
(n 5 128),
n (%)
(n 5 20),
n (%) pAge, years $60 32 (26%) 14 (70%) 0.0001
0 51 (32%) 2 (10%)HCT-CI scores 1-2 42 (37%) 7 (35%) 0.05
$3 35 (31%) 11 (55%)Response to last
treatment
prior to HCTRelapse/
refractory73 (57%) 12 (60%) 0.80CR or PR 55 (43%) 8 (40%)
Fludarabine-refractory Yes 117 (91%) 20 (100%) 0.17
Lymph node size
$5 cmYes 33 (26%) 6 (30%) 0.69Campath within
12 months prior
to HCTYes 30 (23%) 5 (25%) 0.88Donor type Unrelated 55 (43%) 14 (70%) 0.02
Chromosomal
abnormalities
Unfavorable* 50 (64%) 19 (95%) 0.0002Favorable† 78 (36%) 1 (5%)*Includes deletion 17p, P53 mutation, deletion 11q23, or more than 3
cytogenetic abnormalities.
†Includes deletion 13q, normal chromosomes, and triosomy 12.
After a median follow up of 13.6 (range: 3.4-26.5) months follow-
ing HCT, none of the 20 pts have experienced progression or
S290 Poster Session Irelapse. Five pts have died (median 9 months), 2 from graft-versus-
host disease (GVHD), 2 infections, and 1 elected Hospice care after
experiencing renal failure. Last disease responses were complete re-
mission (n5 8), partial remission (n5 6), stable disease (n5 5), not-
evaluated (n 5 1). The incidences of grades II and III-IV acute
GVHD were 60% and 15% respectively, and chronic GVHD was
46% at 1-year. Estimated 1-year rate of non-relapse mortality
(NRM), relapse, progression-free (PFS), and overall survivals (OS)
were 33%, 0%, 67%, and 67% respectively. Patients receiving
peri-HCT rituximab had lower HR for relapse (HR:0, p 5 0.001),
comparable HR for NRM (HR:1, p 5 0.9) and OS (HR:0.7, p 5
0.45), and a trend for lower HR for PFS (HR:0.5, p 5 0.07)
compared to the historical control group. At day 84, median CD3
chimerisms were 99% vs 95% (p 5 0.08), respectively.
After adjusting for the previous 4 significant covariates, PFS was
better (HR:0.4, p 5 0.04) among the rituximab group. Peri-
transplant rituximab is a promising addition to nonmyeloablative
HCT and may decrease early disease progression by allowing the
generation of potent GVL effects.231
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Leukemic transformation (LT) is a rare but fatal complication of
Philadelphia-negative myeloproliferative neoplasms (MPNs) for
which optimal treatment strategies are not known. LT is generally
considered incurable with induction chemotherapy alone.
At our centre, we have adopted a treatment strategy for LT
where patients within the transplant age group who have a reason-
able fitness level are offered induction therapy. Subsequently, those
who achieve complete remission (CR/CRi) or revert back to
a chronic MPN (cMPN) state are considered eligible for allogeneic
transplantation (allo-SCT) if a suitable related or unrelated donor
is available. Alternatively, those who are not candidates for the
aforementioned strategy are offered supportive therapy including
clinical trials.
We evaluated clinical outcomes of this treatment approach in 75
patients with LT diagnosed between 1998 and 2011. Prior to LT,
MPN diagnoses were: PV, 16%; ET, 16%; primary MF, 28%;
post-PV/ET MF, 25%; and MPN-U, 15%. 39 (52%) patients
were treated with curative intent (induction chemotherapy +/-
allo-SCT) while the remainder were treated with non-curative in-
tent. At the time of LT, the curative intent cohort differed from
the non-curative group in terms of median age (57 vs. 72 yrs,
P\0.0001), performance status (ECOG#1 in 92% vs. 58%, p 5
0.001), serum albumin (38 vs. 35 g/L, p 5 0.008) and the frequency
of normal cytogenetics (47% vs. 20%, p 5 0.03) respectively.
Among all patients, the 2-year overall survival (OS) from the time
of LT was 15%. Outcomes were significantly improved in individ-
uals treated with curative vs. non-curative intent (2-year OS, 25%
vs. 4%, P\ 0.0001). Among the curative group, 30/39 achieved ei-
ther CR (n 5 19) or reversion to cMPN (n 5 11). Suitable donors
were identified for 24 (80%) of these responders and 17 (57%) un-
derwent allo-SCT.Median time to transplant was 177 days. Survival
of patients undergoing allo-SCT was significantly better compared
to those who achievedCR/cMPNpost-induction but were not trans-
planted (2-year OS, 46% (n5 17) vs. 15% (n5 13), P5 0.035). To
avoid a time to transplant bias, a landmark analysis was done compar-
ing survival between the transplant cohort and non-transplanted pa-
tients who survived at least 177 days (n5 13), and similar results were
observed (2-year OS 46% vs. 15%, p 5 0.035).
Our results demonstrate the curative potential of intensive induc-
tion therapy followed by allo-SCT in select patients with LT pre-
ceded by MPN.232
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Background:CAYA with ALL or AML in third complete remission
(CR3), refractory relapse (RR) or induction failure (IF) have an ex-
tremely poor prognosis,\20% EFS (Gaynon, BJH, 2005, Wells et
al, JCO, 2003). MAC prior to AlloSCT is associated with high
TRM and is donor dependent: 5-20% for matched sibling, 10-
40% for matched unrelated, and 20-52% for cord blood transplants.
CLO, an inhibitor of DNA polymerase and ribonucleotide reduc-
tase, has been shown to be safe and induce durable remissions,
both in conjunction with busulfan in poor-risk AML (Magenau et
al., Blood, 2011) and with Melphalan in poor-risk hematologic ma-
lignancies in adults (van Besien et al, ASH,2009). CLO has signifi-
cant activity in CAYA with relapsed ALL/AML (Jeha et al., JCO
2006,2009) and synergy with cytarabine (Faderl et al, Blood,
2005). We sought to determine safety, day-100 TRM, and overall
survival (OS) of CLO, cytarabine and TBI followed by AlloSCT in
CAYA with poor-risk ALL/AML.
Methods: This is an ongoing multi-center phase I/II trial of a novel
conditioning regimen of CLO (dose escalation: 40mg/m2 [n5 3], 46
mg/m2 [n 5 3], 52 mg/m2 [n 5 17]) x5d, sequential (4 hrs later) cy-
tarabine 1000 mg/m2 x6d and TBI (1200cGy) followed by AlloSCT
frommatched related or unrelated donors in CAYA with ALL/AML
in CR3, RR or IF. Pts with unrelated grafts received R-ATG.
GVHDprophylaxis consisted of tacrolimus andMMF (Bhatia/Cairo
et al., BBMT, 2009). Kaplan-Meier method was used to determine
the probabilities of engraftment, GVHD, TRM and OS.
Results: 23 pts, median age: 10.8 yrs (1.5-20.7); M:F: 17:6, ALL/
AML: 20:3 (9 CR3, 3 RR, 11 IF), 9 related donors, 14 unrelated do-
nors (8 BM/PBSCs, 6 UCB). Median TNC and CD34 dose was
4.76x108/kg and 4.84x106/kg for BM/PBSCs and 4.0x107/kg and
2.8x105/kg for UCB, respectively. Probabilities of neutrophil and
platelet engraftment and grade II-IV aGVHD were 100%, 92.8%
and 50.8%, respectively. All except one achieved 100% whole blood
donor chimerism by day 30. CLO dose was tolerable at 52mg/m2/
d x5d without dose limiting toxicity. Probability of Day 100 TRM
was only 5%. Probability of 1-yr PFS and OS were 45% (CI95: 24-
83%), and 44.6% (CI95: 24-68%) respectively.
Conclusions: Preliminary results suggest this novel MAC regimen
followed by AlloSCT is safe and well tolerated in CAYA with
poor-risk ALL/ AML with CLO dose of 52 mg/m2. Early results
are encouraging with respect to low risk of day 100 TRM with this
conditioning regimen in this poor-risk population.233
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There has been a marked change in transplant approaches of the
CLL patient. MA conditioning has been shown to provide high
